Cyberonics Inc

Cyberonics — Merger or Acquisition (September 2015)

37 slides from Cyberonics's merger presentation, Sep 10, 2015

  1. Slide 1: Slide 1

  2. Slide 2: Creating LivaNova, a Premier Global Medical Technology Company

    CREATING LIVANOVA, A PREMIER GLOBAL MEDICAL TECHNOLOGY COMPANY

  3. Slide 3: Important Information for Investors and Shareholders

    Important Information for Investors and Shareholders This presentation is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solici

  4. Slide 4: Cyberonics SORINGROUP

    Cyberonics SORINGROUP DF soRING: Cyberonics

  5. Slide 5: Sorin Group and Cyberonics to create LivaNova, a leading global medtech company

    • Diverse, market-leading product portfolio to drive shareholder value • Technical and commercial scale across geographies to enhance revenue growth • Focused innovation platform to exploit market opportunities and accelerate product development in Heart Failure, Sleep Apnea and Percutaneous Mitral

  6. Slide 6: Cyberonics

    Cyberonics

  7. Slide 7: Compelling strategic rationale

    Leadership in Large and Growing Markets Opportunities in Three Multi-Billion Dollar Specialty Markets Global Scale and Geographic Diversification Highly Complementary Technologies Strong Balance Sheet to Execute Plan Compelling strategic rationale

  8. Slide 8: Cyberoni¢s’

    Cyberoni¢s’

  9. Slide 9: Cyberonics and Sorin at a glance

    FY revenues Cyberonics and Sorin at a glance 1) FY 2015 figures as of April 24 , 2015 for Cyberonics. FY 2014 figures as of December 2014 for Sorin translated at an average exchange rate of $1.33/€1 Sutureless valve (Perceval ) and Goal- Directed-Perfusion system CRT optimization system (SonR ) Neur

  10. Slide 10: SORIN Cyberofi¢s'

    SORIN Cyberofi¢s'

  11. Slide 11: Global scale and geographical diversification

    Global scale and geographical diversification São Paulo, Brazil Cyberonics Manufacturing and offices Sorin Manufacturing and R&D Vancouver, BC Denver, CO Houston, TX Costa Rica Mirandola, Italy Meylan, France Saluggia, Italy Munich, Germany Clamart, France Louvain-la-Neuve, Belgium Dominican Republi

  12. Slide 12: Cyberonics

    Cyberonics SORINGROUP O O Cyberoni¢s

  13. Slide 13: Highly complementary businesses

    Highly complementary businesses … 1) FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014 figures as of 31st December 2014 for Sorin translated at an average exchange rate of $1.33/€1 Geography Business Unit Revenues : $292m Neuromodulation 100% International 19% US 81% Revenues : $998m Int

  14. Slide 14: Cyberonics

    Cyberonics

  15. Slide 15: Diversified product portfolio and broader geographical reach

    Europe 43% US 36% Rest of World 21% $1.3bn ...leading to diversified product portfolio and broader geographical reach Pro forma revenues by geography Pro forma revenues by business 1) FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014 figures as of 31st December 2014 for Sorin translated

  16. Slide 16: Position

    Position Cyberoni¢s

  17. Slide 17: Bringing together global leaders in Cardiac Surgery and Neuromodulation

    • Bringing together global leaders in Cardiac Surgery and Neuromodulation • Leveraging an innovative Cardiac Rhythm Management platform Leadership in large and growing markets CARDIAC SURGERY NEUROMODULATION CRM Cardiopulmonary global leader – #1 in Heart-lung machines – #1 in Oxygenators Leading pl

  18. Slide 18: saniiqedes Sujapel sales

    2 ic 2 o 2 > (6) saniiqedes Sujapel 9 sales S2UOIJAQAD | WHAT NiGSS 4

  19. Slide 19: Highly complementary technologies and selling capabilities

    Wireless MRI-Compatibility Remote Monitoring ICD Leads VNS Science and Expertise Algorithms Closed- loop Rechargeable Highly complementary technologies and selling capabilities Shared technologies Complementary commercialization capabilities Implantable electronics Neuromodulation Heart Failure Slee

  20. Slide 20: # SORINGROUP Cyberonics

    # SORINGROUP Cyberonics

  21. Slide 21: Opportunities in billion dollar specialty markets

    Heart Failure (HF) Sleep Apnea Percutaneous Mitral • Accelerated development and commercialization of new product categories • The combined opportunities leverage Cyberonics’ ability to develop markets and Sorin’s geographical reach Opportunities in billion dollar specialty markets Potential market

  22. Slide 22: SORINGHOUP

    SORINGHOUP Cyberoni¢s

  23. Slide 23: Operating synergies driving significant incremental value

    Manufacturing Neuromodulation revenue Heart failure Corporate overhead R&D optimization ~$80 million of annual pre-tax operating synergies to be delivered by the end of 2018 Operating synergies driving significant incremental value Cyberonics’ leverage of Sorin’s commercialization network Capitalizi

  24. Slide 24: Slide 24

  25. Slide 25: Experienced, world-class management team

    Experienced, world-class management team André-Michel Ballester Chief Executive Officer Dan Moore Non-Executive Chairman of the Board Ed Andrle Strategy, Business Development and New Ventures/Emerging Therapies Brian Sheridan General Counsel Pritpal Shinmar Global Market Access David Wise HR & IT De

  26. Slide 26: Cyberonics

    Cyberonics

  27. Slide 27: Transaction overview

    LivaNova PLC domicile and listing • Incorporated in the UK and UK tax resident • Dual listed on Nasdaq and London Stock Exchange Exchange ratio • 1:1 of LivaNova stock for Cyberonics shareholders • 0.0472:1 of LivaNova stock for Sorin shareholders Ownership • Cyberonics shareholders: ~ 54% • Sorin s

  28. Slide 28: @e@OG

    @e@OG Cyberonics

  29. Slide 29: Transaction timeline: closing expected in Q4 2015

    Unanimous approval by BoD and deal announcement 26 Feb US Antitrust approval 14 April LivaNova management and integration team announced 12 May Sorin EGM approved proposed merger 26 May End of 15-day Sorin Shareholder Withdrawal Right period 12 June End of 60-day Sorin Creditor Rights period 27 July

  30. Slide 30: Cyberonics

    Cyberonics

  31. Slide 31: Driving significant shareholder returns

    Revenue growth acceleration Synergies EPS impact Balance Sheet implications Driving significant shareholder returns • Stronger and more diversified platform for growth • Significant revenue potential from highly complementary Heart Failure programs • Leverage Sorin’s commercialization network for Ne

  32. Slide 32: Cyberoni¢s

    Cyberoni¢s

  33. Slide 33: Sorin Q2 2015 Results

    Value Change Sorin Q2 2015 Results * Ended June 30, 2015 • Robust revenue growth in Cardiac Surgery (€146.7m, +5.5%°) – Strong momentum in cardiopulmonary • Solid results in Cardiac Rhythm Management (€68.3m, +4.6%°) – Growth in Low-Voltage • Successful roll-out of Inspire in Europe, the US and Japa

  34. Slide 34: DPE soRINGS Cyberoni¢és

    DPE soRINGS Cyberoni¢és

  35. Slide 35: Cyberonics Q1 2016 Results

    Value Change Cyberonics Q1 2016 Results * Ended July 24, 2015 • Record net sales of $81m over the quarter • Record U.S. net product sales of $67.7m (+15%) • Driven by very strong demand for the AspireSR® generator • International net sales up 11.4% on a constant currency basis • Initial launch of Vi

  36. Slide 36: Cyberoni¢s

    Cyberoni¢s

  37. Slide 37: Contacts

    Contacts FOR SORIN GROUP: Investors: Demetrio Mauro CFO Sorin Group Tel: +39 02 69969 512 e-mail: investor.relations@sorin.com Francesca Rambaudi Director, Investor Relations Sorin Group Tel: +39 02 69969 716 e-mail: investor.relations@sorin.com Media: Gabriele Mazzoletti Director, Corporate Communi

Cyberonics — Merger or Acquisition (September 2015) on 6ix